Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMRANASDAQ:LEGNNASDAQ:TLXNASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMRAIMARA$59.11-0.6%$17.12$0.97▼$6.32$1.55B1.09138,364 shs123 shsLEGNLegend Biotech$27.80-10.6%$33.79$27.54▼$60.87$5.11B0.21.27 million shs4.18 million shsTLXTelix Pharmaceuticals Limited American Depositary Shares$16.40-1.9%$17.02$13.61▼$30.36$5.54BN/A27,092 shs9,162 shsVRNAVerona Pharma$67.24-0.5%$63.34$11.39▼$74.18$5.45B0.21.29 million shs1.31 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMRAIMARA+0.23%+9.49%+18.84%+840.58%+840.58%LEGNLegend Biotech-10.55%-11.66%-13.42%-23.61%-37.36%TLXTelix Pharmaceuticals Limited American Depositary Shares-1.86%-7.61%-2.61%-5.15%+1,639,999,900.00%VRNAVerona Pharma-0.49%-2.75%+16.31%+9.03%+384.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMRAIMARAN/AN/AN/AN/AN/AN/AN/AN/ALEGNLegend Biotech3.6458 of 5 stars4.54.00.00.02.91.70.6TLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/AN/AN/AN/AN/AN/AN/AVRNAVerona Pharma3.1222 of 5 stars3.63.00.00.03.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMRAIMARA 0.00N/AN/AN/ALEGNLegend Biotech 2.92Moderate Buy$74.73168.80% UpsideTLXTelix Pharmaceuticals Limited American Depositary Shares 3.00Buy$22.0034.15% UpsideVRNAVerona Pharma 3.11Buy$81.5021.21% UpsideCurrent Analyst Ratings BreakdownLatest IMRA, LEGN, TLX, and VRNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025LEGNLegend BiotechTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$88.00 ➝ $71.005/14/2025LEGNLegend BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$55.00 ➝ $55.004/30/2025VRNAVerona PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$93.00 ➝ $107.004/30/2025VRNAVerona PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$75.00 ➝ $85.004/28/2025VRNAVerona PharmaCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy4/28/2025VRNAVerona PharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$100.004/22/2025LEGNLegend BiotechRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$84.00 ➝ $84.004/21/2025VRNAVerona PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$80.004/16/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.004/8/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.003/17/2025LEGNLegend BiotechMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$82.00 ➝ $80.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMRAIMARAN/AN/A$0.79 per share75.24$3.44 per shareN/ALEGNLegend Biotech$627.24M8.14N/AN/A$6.88 per share4.04TLXTelix Pharmaceuticals Limited American Depositary Shares$783.21M7.08N/AN/AN/A∞VRNAVerona Pharma$118.54M45.99N/AN/A$3.10 per share21.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMRAIMARA$1.49M$0.051,182.49∞N/AN/A2.12%2.00%N/ALEGNLegend Biotech-$518.25M-$0.48N/AN/AN/A-66.92%-29.69%-19.45%N/ATLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/A0.0034.17N/AN/AN/AN/AN/AVRNAVerona Pharma-$54.37M-$2.00N/A2,241.33N/AN/A-79.54%-43.49%N/ALatest IMRA, LEGN, TLX, and VRNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025LEGNLegend Biotech-$0.40-$0.07+$0.33-$0.27$190.83 million$195.05 million4/29/2025Q1 2025VRNAVerona Pharma-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 million3/11/2025Q4 2024LEGNLegend Biotech-$0.39$0.07+$0.46$0.07$179.00 million$186.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMRAIMARAN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ATLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/AN/AN/AN/AVRNAVerona PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMRAIMARAN/A48.9848.98LEGNLegend Biotech0.274.984.90TLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/AN/AVRNAVerona Pharma0.9313.0312.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMRAIMARA49.28%LEGNLegend Biotech70.89%TLXTelix Pharmaceuticals Limited American Depositary SharesN/AVRNAVerona Pharma85.88%Insider OwnershipCompanyInsider OwnershipIMRAIMARA37.30%LEGNLegend Biotech0.02%TLXTelix Pharmaceuticals Limited American Depositary SharesN/AVRNAVerona Pharma4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMRAIMARA4126.23 million16.45 millionNot OptionableLEGNLegend Biotech1,070183.65 million182.60 millionOptionableTLXTelix Pharmaceuticals Limited American Depositary SharesN/A337.88 millionN/AN/AVRNAVerona Pharma3081.08 million76.10 millionOptionableIMRA, LEGN, TLX, and VRNA HeadlinesRecent News About These CompaniesRaymond James Financial Inc. Invests $225,000 in Verona Pharma plc (NASDAQ:VRNA)May 15 at 3:06 AM | marketbeat.comWhy Verona Pharma plc (VRNA) is Among the Best Performing Healthcare Stocks to Buy NowMay 13 at 12:09 PM | insidermonkey.comFred Alger Management LLC Takes $1.34 Million Position in Verona Pharma plc (NASDAQ:VRNA)May 13 at 6:03 AM | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Shares Acquired by Barclays PLCMay 13 at 3:20 AM | marketbeat.comFindell Capital Management LLC Makes New $8.36 Million Investment in Verona Pharma plc (NASDAQ:VRNA)May 11, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Has $5.89 Million Stock Position in Verona Pharma plc (NASDAQ:VRNA)May 10, 2025 | marketbeat.comDeep Track Capital LP Sells 2,330,025 Shares of Verona Pharma plc (NASDAQ:VRNA)May 9, 2025 | marketbeat.comDuquesne Family Office LLC Purchases 201,535 Shares of Verona Pharma plc (NASDAQ:VRNA)May 9, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Insider Sells $1,014,158.88 in StockMay 9, 2025 | insidertrades.comWhat Makes Verona Pharma plc (VRNA) a Good Investment?May 8, 2025 | insidermonkey.comWhat Makes Verona Pharma plc (VRNA) a Good Investment?May 8, 2025 | msn.comCaxton Associates LP Acquires New Position in Verona Pharma plc (NASDAQ:VRNA)May 8, 2025 | marketbeat.comBeverly Hills Private Wealth LLC Purchases Shares of 5,566 Verona Pharma plc (NASDAQ:VRNA)May 8, 2025 | marketbeat.comAxa S.A. Sells 74,142 Shares of Verona Pharma plc (NASDAQ:VRNA)May 8, 2025 | marketbeat.comVerona Pharma Presents Positive Phase 3 Analyses of Ohtuvayre® for COPD at ATS 2025May 7, 2025 | nasdaq.comVerona Pharma Presents Positive Phase 3 Analyses of Ohtuvayre® for COPD at ATS 2025May 7, 2025 | nasdaq.comBellevue Group AG Trims Holdings in Verona Pharma plc (NASDAQ:VRNA)May 6, 2025 | marketbeat.comVerona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025May 6, 2025 | globenewswire.comSchonfeld Strategic Advisors LLC Increases Stock Holdings in Verona Pharma plc (NASDAQ:VRNA)May 6, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Sees Large Decline in Short InterestMay 5, 2025 | marketbeat.comVoya Investment Management LLC Has $2.77 Million Position in Verona Pharma plc (NASDAQ:VRNA)May 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMRA, LEGN, TLX, and VRNA Company DescriptionsIMARA NASDAQ:IMRAIMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2-related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Legend Biotech NASDAQ:LEGN$27.80 -3.28 (-10.55%) As of 05/14/2025 04:00 PM EasternLegend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Telix Pharmaceuticals Limited American Depositary Shares NASDAQ:TLX$16.40 -0.31 (-1.86%) As of 05/14/2025 04:00 PM EasternTelix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.Verona Pharma NASDAQ:VRNA$67.24 -0.33 (-0.49%) As of 05/14/2025 04:00 PM EasternVerona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
